GlassScriptPhysician profile
Marc L Cohen
NPI 1942461165
$13,405.51
in general payments reported to CMS, 2019-2025
63 companies · $2,898 in 2025
The $2,898 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,191 · 2020: $862 · 2021: $605 · 2022: $1,018 · 2023: $2,452 · 2024: $3,379 · 2025: $2,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,380 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,379.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,873.41 | 2019-2025 | Ubrelvy, Qulipta, Duopa |
| Emd Serono, INC. | $1,232.95 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $931.15 | 2019-2025 | |
| Genzyme Corporation | $813.51 | 2019-2023 | |
| Biogen, INC. | $797.27 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Ucb, INC. | $788.30 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Mdd US Operations, LLC | $787.18 | 2019-2025 | Apokyn, Apokyn |
| Amgen INC. | $467.40 | 2019-2025 | Uplizna, Aimovig |
| Livanova USA, INC. | $423.18 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $407.04 | 2020-2025 | Ultomiris, Soliris |
| Catalyst Pharmaceuticals, INC. | $358.16 | 2020-2025 | Fycompa |
| Eisai INC. | $318.70 | 2019-2024 | |
| Lilly USA, LLC | $279.11 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Neurelis, INC. | $263.27 | 2020-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $257.79 | 2019-2025 | Ingrezza, Ongentys |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.